One approach is tumor-targeting, covering both heme malignancies (CD19) and solid tumors (PD-L1, Her2, FAP, EGFR, PSMA, Cldn18.2, Nectin 4, B7H4, CEACAM5, 5T4, EphA2). The gene discussed is ERBB2; the disease is neoplasm.